I Treilleux1, M Arnedos2, C Cropet3, Q Wang4, J-M Ferrero5, S Abadie-Lacourtoisie6, C Levy7, E Legouffe8, A Lortholary9, E Pujade-Lauraine10, A-V Bourcier11, J-C Eymard12, D Spaeth13, T Bachelot14. 1. Department of Anatomopathology, Centre Léon Bérard, Lyon. 2. Oncology Department, Gustave Roussy, Villejuif. 3. Biostatistics and Therapeutic Evaluation Unit. 4. Genomic Platform-Translational Research Laboratory, Centre Léon Bérard, Lyon. 5. Medical Oncology Department, Centre Antoine Lacassagne, Nice. 6. Medical Oncology Department, Centre Paul Papin, Angers. 7. Oncology Department, Centre François Baclesse, Caen. 8. Hematology and Oncology Department, Clinique de Valdegour, Nimes. 9. Oncology Department, Centre Catherine de Sienne, Nantes. 10. Oncology Department, Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, Site Hôtel-Dieu, Paris. 11. Hematology and Oncology Department, Centre Hospitalier Départemental Les Oudairies, La Roche-Sur-Yon. 12. Department of Medicine, Institut Jean Godinot, Reims. 13. Oncology Department, Centre d'Oncologie de Gentilly, Nancy. 14. 2B North Department, Department of Medical Oncology and Cancer Research Center of Lyon, Centre Léon Bérard, Lyon, France. Electronic address: thomas.bachelot@lyon.unicancer.fr.
Abstract
BACKGROUND:Everolimus is an agent frequently associated with specific toxicities. Predictive markers of efficacy are needed to help define which patients could benefit from it. The goal of this exploratory study was to identify potential predictive biomarkers in the mammalian target of rapamycin (mTOR) complex 1 (mTORC1) activation pathway using primary tumor samples collected during the phase II tamoxifen plus everolimus (TAMRAD) trial. PATIENTS AND METHODS: Tumor tissues were collected retrospectively from the TAMRAD trial. Immunohistochemistry was carried out using specific antibodies directed toward proteins that result in mTORC1 activation [canonical phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mTOR or alternative pathways]. DNA was extracted from the tumor tissue; mutation screening in the PIK3CA gene (exons 9 and 20) and the KRAS gene (exons 2 and 3) was first carried out using Sanger direct sequencing, and then completed by next-generation sequencing for PIK3CA. An exploratory analysis of everolimus efficacy in terms of a time-to-progression (TTP) increase was carried out in each biomarker subgroup (high versus low expression referring to the median percentage of marked cells). RESULTS: A total of 55 primary tumor samples from the TAMRAD trial—25 from the tamoxifen-alone group and 30 from the tamoxifen/everolimus group—were evaluated for biomarkers. The subgroups most likely to have an improvement in TTP with tamoxifen/everolimus therapy, compared with tamoxifen alone, were patients with high p4EBP1, low 4EBP1, low liver kinase B1, low pAkt, and low PI3K. Among the 45 samples screened for mutation status, nine samples (20%; 95% CI 9.6-34.6) had a PIK3CA mutation. KRAS mutation was observed in one patient. CONCLUSIONS: A positive correlation between late effectors of mTORC1 activation, a positive correlation between Akt-independent mTORC1 activation, and an inverse correlation between canonical PI3K/Akt/mTOR pathway and everolimus efficacy were observed in this exploratory analysis. However, these correlations need to be validated in larger studies before applying the findings to routine clinical practice.
RCT Entities:
BACKGROUND:Everolimus is an agent frequently associated with specific toxicities. Predictive markers of efficacy are needed to help define which patients could benefit from it. The goal of this exploratory study was to identify potential predictive biomarkers in the mammalian target of rapamycin (mTOR) complex 1 (mTORC1) activation pathway using primary tumor samples collected during the phase II tamoxifen plus everolimus (TAMRAD) trial. PATIENTS AND METHODS: Tumor tissues were collected retrospectively from the TAMRAD trial. Immunohistochemistry was carried out using specific antibodies directed toward proteins that result in mTORC1 activation [canonical phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mTOR or alternative pathways]. DNA was extracted from the tumor tissue; mutation screening in the PIK3CA gene (exons 9 and 20) and the KRAS gene (exons 2 and 3) was first carried out using Sanger direct sequencing, and then completed by next-generation sequencing for PIK3CA. An exploratory analysis of everolimus efficacy in terms of a time-to-progression (TTP) increase was carried out in each biomarker subgroup (high versus low expression referring to the median percentage of marked cells). RESULTS: A total of 55 primary tumor samples from the TAMRAD trial—25 from the tamoxifen-alone group and 30 from the tamoxifen/everolimus group—were evaluated for biomarkers. The subgroups most likely to have an improvement in TTP with tamoxifen/everolimus therapy, compared with tamoxifen alone, were patients with high p4EBP1, low 4EBP1, low liver kinase B1, low pAkt, and low PI3K. Among the 45 samples screened for mutation status, nine samples (20%; 95% CI 9.6-34.6) had a PIK3CA mutation. KRAS mutation was observed in one patient. CONCLUSIONS: A positive correlation between late effectors of mTORC1 activation, a positive correlation between Akt-independent mTORC1 activation, and an inverse correlation between canonical PI3K/Akt/mTOR pathway and everolimus efficacy were observed in this exploratory analysis. However, these correlations need to be validated in larger studies before applying the findings to routine clinical practice.
Authors: Linda S Steelman; Alberto M Martelli; Lucio Cocco; Massimo Libra; Ferdinando Nicoletti; Stephen L Abrams; James A McCubrey Journal: Br J Clin Pharmacol Date: 2016-05-10 Impact factor: 4.335
Authors: Christopher D Hart; Ilenia Migliaccio; Luca Malorni; Cristina Guarducci; Laura Biganzoli; Angelo Di Leo Journal: Nat Rev Clin Oncol Date: 2015-05-26 Impact factor: 66.675
Authors: Emre Koca; Polly Ann Niravath; Joe Ensor; Tejal Amar Patel; Xiaoxian Li; Pej Hemati; Helen Wong; Wei Qian; Toniva Boone; Jing Zhao; Priya V Ramshesh; Adam Louis Cohen; Asha Murthy; Sindhu Nair; Jorge German Darcourt; Anna Belcheva; Virginia G Kaklamani; Jenny Chee Ning Chang Journal: Breast Cancer Res Treat Date: 2021-04-15 Impact factor: 4.624